ClinicalTrials.gg
Active, not recruitingNCT07134478Updated Dec 31, 2025

Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects

A Phase 1 interventional study of HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi in Healthy Subjects, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2024, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, open-label, two-period, fixed-sequence clinical study to evaluate the effect of Rifampicin on the pharmacokinetics of HSK31858 in healthy subjects

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, aged 18 to 45 years (inclusive) at screening;
  • Body weight ≥ 50 kg for males and ≥ 45 kg for females at screening; (BMI = weight (kg)/height2 (m2)) should be within the range of 19.0-26.0 kg/m2 (inclusive);
  • Subjects (including their partners) agree to have no fertility plan, no sperm or egg donation plans, and take effective non-drug measures (including complete abstinence, condoms, intrauterine device, partner sterilization, etc.) during the study and within 3 months after the last dose;
  • Fully understand the purpose, requirements and potential risks of this study, voluntarily participate in the clinical study, and be able to sign the form (ICF) before the study;

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known allergy to HSK31858 tablets, rifampicin capsules, or any component of similar drugs and preparations, or those with an allergic constitution (e.g., allergies to two or more drugs or food allergies); or those with a history of specific allergies (e.g., asthma, urticaria, eczema, etc.);
  • Subjects who have special dietary requirements and cannot follow a uniform diet (including those with lactose intolerance); or those with dysphagia;
  • Subjects with abnormalities in vital signs, physical examination, laboratory tests (blood routine test, blood biochemistry, coagulation function, urinalysis), 12-lead , chest X-ray (anteroposterior), or color ultrasonography, which are inappropriate for participation in this study as judged by the investigator;
  • Subjects who have excessively consumed tea, coffee, or caffeinated beverages (more than 4 cups per day, 1 cup = 250 mL) within 3 months prior to screening; or who have consumed tea or any food or beverage containing caffeine (such as coffee, chocolate, etc.) within 48 hours prior to the first dose; or who do not agree to stop consuming tea, coffee or food or beverages containing caffeine during the study;
  • Subjects who have consumed large amounts of grapefruit-rich beverages or food (such as grapefruit, grapefruit juice, grapefruit jam, etc.) within 14 days prior to screening; or who have consumed any grapefruit-rich beverages or food within 48 hours prior to the first dose; or who do not agree to stop consuming any grapefruit-rich beverages or food during the study;
  • Subjects with a history or current diagnosis of significant cardiovascular, respiratory, digestive, urinary, hematological, endocrine, immune, dermatologic, or neurologic disease, including those who have undergone major surgery within 3 months prior to screening or whose surgical incision has not completely healed;
  • Subjects with a history or current diagnosis of gastrointestinal, liver, kidney, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion;
  • Subjects previously diagnosed with periodontitis or/and palmoplantar hyperkeratoses;
  • Subjects who have donated or lost blood ≥ 400 mL within 3 months prior to screening or plan to donate blood during the study, or who have received blood transfusion or used blood products within 3 months prior to screening;
  • Subjects who have used any drug that inhibits or induces hepatic CYP enzymes (e.g., inducers-rifampicin, dexamethasone, carbamazepine, phenytoin, fosphenytoin, primidone, enzalutamide, St. John's Wort, etc.; CYP3A4 inhibitors-itraconazole, ketoconazole, voriconazole, erythromycin, clarithromycin, ritonavir, etc.) within 28 days prior to screening or within 5 half-lives of the drug (whichever is longer), or who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicine, or health care products other than those listed above within 14 days prior to screening or within 5 half-lives of the drug (whichever is longer);
  • Subjects who have participated in other drug clinical studies within 3 months prior to screening; or who plan to participate in other clinical studies during the study;
  • Subjects who have been vaccinated within 1 month before screening, or who plan to be vaccinated during the study;
  • Subjects with a history of drug addiction, drug abuse, or drug dependence, or who have a positive drug abuse screening at screening;
  • Subjects who have frequently consumed alcohol within 3 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or who cannot abstain from alcohol during the study, or who have a positive breath alcohol test at screening;
  • Subjects who have smoked more than 5 cigarettes per day (or equivalent amount of nicotine-containing products) within 3 months prior to screening, or who cannot abstain from smoking during the study;
  • Subjects who are tested positive for one or more of the following at screening: virus surface antigen, virus antibody, antibody, and Treponema pallidum antibody;
  • Subjects with a history of needle sickness or blood sickness, difficulty in blood collection, or intolerance to blood collection by venipuncture;
  • Subjects with tattoos or scars on any site of the skin that affect safety assessment as judged by the investigator;
  • Women who are pregnant or breastfeeding; or those with a positive pregnancy test; Subjects who, in the investigator's opinion, have poor compliance or other factors that make them unsuitable for participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    combination drug;

    HSK31858 Tablets and Rifampicin Capsules

    Drug: HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    The pharmacokinetic parameters of unchanged HSK31858 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  2. AUC(0-∞)

    The pharmacokinetic parameters of unchanged HSK31858 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

Secondary outcomes

  1. AUC(0-t)

    The pharmacokinetic parameters of unchanged HSK31858 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  2. Tmax

    The pharmacokinetic parameters of unchanged HSK31858 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  3. t1/2

    The pharmacokinetic parameters of unchanged HSK31858 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  4. Cmax

    The pharmacokinetic parameters of metabolite M4 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  5. AUC(0-∞)

    The pharmacokinetic parameters of metabolite M4 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  6. Tmax

    The pharmacokinetic parameters of metabolite M4 in plasma

    Time frame: [Time Frame: From the start of administration to 96 hours post-dose]

  7. AEs

    The incidence and severity of AEs

    Time frame: [Time Frame: From the time of signing ICF to the end of follow-up,up to 25 days]

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Oct 28, 2024
Primary completionActual
Dec 24, 2024
CompletionEst.
Jun 1, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134478
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Oct 28, 2024
Primary completion
Dec 24, 2024
Completion
Jun 1, 2026 (estimated)
Last update
Dec 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion